T3 병기의 직장암 환자에서 예후인자로서의 직장간막 침범깊이 by 신루미
 
 
저 시-비 리-동 조건 경허락 2.0 한민  
는 아래  조건  르는 경 에 한하여 게 
l  저 물  복제, 포, 전송, 전시, 공연  송할 수 습니다.  
l 차적 저 물  성할 수 습니다.  
다 과 같  조건  라야 합니다: 
l 하는,  저 물  나 포  경 ,  저 물에 적  허락조건
 확하게 나타내어야 합니다.  
l 저 터  허가를  러한 조건들  적 지 않습니다.  
저 에 른  리는  내 에 하여 향  지 않습니다. 




저 시. 하는 원저 를 시하여야 합니다. 
비 리. 하는  저 물  리 적  할 수 없습니다. 
동 조건 경허락. 하가  저 물  개 , 형 또는 가공했  경






Depth of mesorectal extension has 
prognostic significance in patients 
with T3 rectal cancer 
  
T3 병기의 직장암 환자에서 







의학과 석사 과정 
신  루  미 
ii 
 
T3 병기의 직장암 환자에서 
예후인자로서의 직장간막 침범깊이 
 
 
Depth of mesorectal extension has 
prognostic significance in patients 









The Department of Surgery,  
Seoul National University 




T3 병기의 직장암 환자에서 




지도 교수  박 재 갑 
 





의학과 외과학 전공 
신 루 미 
 
 
신루미의 의학석사 학위논문을 인준함 
2012년 12월 
 
위 원 장                           (인) 
부위원장                           (인) 






Depth of mesorectal extension has 
prognostic significance in patients 




Rumi Shin, MD. 
A thesis submitted to the Department of Surgery in 
partial fulfillment of the requirements for the Degree of 
Master of Science in Surgery at Seoul National University 







Approved by Thesis Committee: 
 
Professor                    Chairman 
Professor                    Vice chairman 







Introduction : More than half of all rectal cancers are T3 lesions, but 
they are classified as a single stage category. In the case of rectal cancer, 
some authors reported a prognostic influence of the mesorectal 
infiltration depth and have suggested that this parameter should be 
included in therapeutic decision-making. The aim of this study was to 
validate prognostic significance of mesorectal extension depth in T3 
rectal cancer. 
Methods:  We studied 291 patients with T3 rectal cancer who 
underwent a curative intent surgery between January 2003 and 
December 2009 at Seoul National University Hospital. This study is a 
retrospective analysis of oncologic outcomes of patients with T3 rectal 
cancer grouped by mesorectal extension depth (T3a: <1mm, T3b: 
1~5mm, T3c: 5~15mm, T3d: >15mm). Oncologic outcomes in terms of 
disease-free survival were analyzed. 
Results: The 5-year disease free survival rate according to T3 
subclassification was 86.5 % for T3a, 74.2 % for T3b, 58.3 % for T3c 
and 29.0 % for T3d, respectively. It was significantly higher in T3a, b 
tumors than that in T3c, d tumors (77.6% vs. 55.2%, p<0.001). On 
univariate and multivariate analysis, prognostic factors affecting 
recurrence were preoperative carcinoembryonic antigen (CEA) level ≥ 
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5ng/ml (hazard ratio =2.617, 95% CI 1.620-4.226), lymph node 
metastasis (hazard ratio =3.347, 95% CI 1.834-6.566) and mesorectal 
extension depth >5mm (hazard ratio =1.661, 95% CI 1.013-2.725). In 
subgroup analysis, independent prognostic factors were preoperative 
CEA level and mesorectal extension depth >5mm for 200 ypT3 rectal 
cancer patients and preoperative CEA level and lymph node metastasis 
for 91 pT3 rectal cancer patients. 
Conclusions: Depth of mesorectal extension >5mm is a significant 
prognostic factor in patients with T3 rectal cancer. Especially, depth of 
mesorectal extension may be more important than the nodal status in 
predicting the oncologic outcome for patients who had received 
preoperative chemoradiotherapy. 
* This work is published in Disease of colon & rectum Journal (Dis Colon 
Rectum 2012; 55: 1220–1228). 
------------------------------------- 
Keywords: T3 substaging, rectal cancer, preoperative 
chemoradiotherapy, prognostic factor, recurrence, mesorectal 
extension depth 
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Current TNM staging system has been regarded as a standard staging system 
for colorectal cancer ever since its introduction in 1987 by the American Joint 
Committee on Cancer (AJCC) and the International Union Against Cancer 
(UICC) owing to its superb reflection of prognosis. The depth of infiltration 
of primary tumor (T classification) and nodal status (N classification) were 
known as important prognostic factors for local recurrence and distant 
metastasis after surgery in patient with colorectal cancer. In the case of rectal 
cancer, some authors reported a prognostic influence of the mesorectal 
infiltration depth and have suggested that this parameter should be included in 
therapeutic decision making. (1-7) 
In 1993, the UICC proposed optional cut-off points for mesorectal extension 
in the context of pT3 and pT4 tumors.(8) Thereafter, several studies have 
described prognostic heterogeneity in patients with T3 rectal cancer with 
different prognostic cut-off points to subdivide the mesorectal extension depth 
(MED). Those studies used various prognostic cut-off points such as 2mm (2), 
3mm (5, 9), 4mm (4, 6, 7, 10, 11), 5mm(12-14), and 6mm (1). On the 
Surveillance, Epidemiology, and End Results (SEER) database analysis, a 
clear difference in survival rates were found for patients with stage II rectal 
cancer (T4aN0, 55.7 %; T4bN0, 44.7 %) when the T4 tumors were subdivided 
into T4a and T4b according to the invasion or adhesion to adjacent organs or 
structures.(15) Subsequently, these expanded outcomes based on SEER rectal 
and colon cancer database analysis have been reflected in the 7th edition 
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TNM staging system and changed the process of substaging stages II and III. 
However, these subdivided T4 tumors account for only 14.3 % of the entire 
colorectal cancer and T3 tumors which account for more than 60% on SEER 
database were classified as a single stage disease. Furthermore, the reliability 
of several cut-off points for stratifying the mesorectum in T3 tumors remains 
controversial. The aim of present study was to investigate the prognostic 
significance of the MED in T3 rectal cancer. 
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MATERIALS AND METHODS 
1. Patients and Surgical Treatments 
The study was performed in accordance with the guidelines of our 
Institutional Review Board, which deemed that informed consent was not 
required. We retrospectively studied 291 patients with T3 rectal cancer who 
underwent a curative intent surgery between January 2003 and December 
2009 at Seoul National University Hospital. All patients had primary rectal 
adenocarcinoma without any evidence of distant metastasis, and located 
within 15cm from the anal verge. A standardized total mesorectal excision 
(TME) technique including high ligations of the inferior mesenteric vessels 
was used in all patients. For patients who underwent preoperative 
chemoradiotherapy (CRT), surgical resection was scheduled between 6 to 8 
weeks after completion of CRT.  
 
2. Preoperative CRT and Adjuvant Therapy 
Radiotherapy was delivered to whole pelvis at a dose of 45 Gy in 25 
fractions, followed by a boost of 5.4 Gy to the primary tumor in 3 fractions 
over 5.5 weeks. One of the following preoperative chemotherapeutic regimens 
was delivered concurrently with radiotherapy: (1) 5-fluorouracil (FU) (2 
cycles of bolus intravenous 5-FU 500 mg/m
2
/d for 3 days in the first and the 
fifth weeks of radiotherapy); (2) capecitabine (oral administration of 
capecitabine 1,650 mg/m
2
 twice daily during radiotherapy with weekend 
breaks). Postoperative adjuvant chemotherapy was started in patients with 
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stage II and III disease within 3-4 weeks after surgery. The regimen is one of 
followings: (1) FL [six cycles of 5- FU 375mg/m
2
/day and leucovorin 
20mg/m
2
/day on D1-5 every week]; (2) FOLFOX [intravenous oxaliplatin 
(85mg/m
2
/day) and leucovorin (400mg/m
2
/day) on the first day, bolus 
intravenous 5-FU (400mg/m
2
/d) on the first day, then continuous infusion of 
1,200mg/m
2
/d for 2 days] ; (3) capecitabine (oral administration of 
capecitabine 2,000-2,500 mg/m
2
/day in two divided doses, D1-14 with 7 day 
rest, repeat every 3 weeks). Postoperative CRT protocol was identical to that 
of preoperative CRT.  
 
3. Measurement of Mesorectal Extension Depth 
T3 tumors were stratified according to the T3 subclassification proposed by 
Hermaneck et al (Table 1).(8) It was subdivided on the basis of the 
histological measurement of the maximum depth of invasion beyond the outer 
border of the muscular layer. Two specialized GI pathologists analyzed the 
depth of tumor invasion by dividing the tumor at the deepest invasion spot 
grossly into four sections in the form of cross. For the depth inspection, they 
put at least four sections; and for the inspection of the entire tumor, they put 
two additional sections making at least six sections. Hematoxylin-and-eosin 






pT3a Minimal Tumor invades through the muscularis propria 
into the subserosa into nonperitonealized pericolic 
or perirectal tissues not >1 mm beyond the outer 
border of muscularis propria 
pT3b Slight Tumor invades through the muscularis propria 
into the subserosa into nonperitonealized pericolic 
or perirectal tissues >1 mm but not >5 mm beyond 
the outer border of muscularis propria 
pT3c Moderate Tumor invades through the muscularis propria 
into the subserosa into nonperitonealized pericolic 
or perirectal tissues >5 mm but not >15 mm 
beyond the outer border of muscularis propria 
pT3d Extensive Tumor invades through the muscularis propria 
into the subserosa into nonperitonealized pericolic 
or perirectal tissues >15 mm beyond the outer 
border of muscularis propria 
 
Table 1. T3 subclassification by Hermaneck et al. 
 
When the outer border of the muscular layer was completely identifiable 
(sometimes identifiable as fragments of muscle), the distance from the outer 
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border of the muscular layer to the deepest part of the invasion was measured. 
If the outer border was not clear, we checked the outer border at both ends of 
tumor where it was clear and drew a tentative line considering it as the outer 
border of muscle layer. For a separate mesorectal tumor nodule to be 
recognized as tumor deposit, it had to be large enough to be recognized as a 
lymph node and freely movable and not continuously connected to the main 
mass. If it was very small and closely located to the main mass, it was 
considered as tumor invasion rather than tumor deposit. 
 
Figure 1. Microscopic subclassification of T3 rectal cancer according to 
the mesorectal extension depth (MED) beyond the outer border of 
muscularis propria is demonstrated.  
(A)  T3a, MED ≤1 mm. (B) T3b, 1 mm < MED ≤5mm. (C)T3c, 5 mm < 
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MED ≤15 mm. (D) T3d, MED >15 mm. 
4. Statistical Analysis 
The Kaplan-Meier method was used for the univariate analysis of the 
prognostic value of sex, age category, subdivided T3 category, lymph 
node involvement, tumor differentiation, angiolymphatic invasion, 
circumferential resection margin and preoperative CRT. The Cox 
regression analysis was used to analyze the independent prognostic 
factors for recurrence-free survival. Statistical analyses were performed 






1.  Clinicopathologic characteristics of patient  
The clinicopathological characteristics of 291 patients [214 males (73.5%), 
mean age = 60.4 ± 11.5 (range, 23~86) years] are shown in Table 2. Mean 
follow-up period of these patients was 43.8 ± 22.9 (range, 4.1-98.3) months.  
Features Number of patients  
(n=291)  
Age, y 60.4 ±11.5  
Follow up period, m 43.8 ±22.9  
Sex     
   Male  214 (73.5)  
   Female  77 (26.5)  
Differentiation     
   G1+G2  274 (94.2)  
   G3+G4  17 (5.8)  
CEA level (ng/ml)  9.3 ±31.4  
Mean number of  
harvested lymph nodes  
16.8 ±10.3  
T3 subclassification    
   T3a  48 (16.5)  
   T3b  128 (44.0)  
   T3c  100 (34.4)  
   T3d  15 (5.2)  
N stage     
   N-  121 (41.6)  
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 N+ 170 (58.4) 
Preoperative CRT
a
    
   No  200 (68.7)  
   Yes  91 (31.3)  
Adjuvant chemotherapy     
   No  39 (12.4)  
   Yes  255 (87.6)  
Operation   
 Anterior resection 7 (2.4) 
 Low anterior resection 255 (87.6) 
 Abdominoperineal resection 18 (6.2) 
 Hartmann procedure 10 (3.4) 
 
Table 2. Clinicopathological characteristics of 291 patients with T3 rectal 
cancer 
 
2. The prognostic factors affecting the recurrence in patient with T3 
rectal cancer  
Postoperative recurrence occurred in 74 patients (25.4%), including 12 
patients (9.9%) in stage IIA, 35 patients (32.1%) in stage IIIB and 27 patients 
(44.3%) in stage IIIC. Eight patients (2.7 %) had local recurrence only, 54 
patients (18.6 %) had distant metastasis only, and 12 patients (4.1 %) had both 
local recurrence and distant metastases.  
Disease-free survival rates according to MED were 86.5 % in T3a, 74.2 % in 
T3b, 58.3 % in T3c, and 29.0 % in T3d (Fig. 2A), respectively. The difference 
was not statistically significant between T3a and T3b, and also between T3c 
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and T3d. However, when re-categorized as T3ab (ME
(MED > 5mm), the 5-year disease-free survival rate of patients with T3ab 
rectal cancer was significantly higher than that of patients with T3cd (77.6% 
vs. 55.2%, respectively, p<0.001) (Fig. 2B). On univariate analysis, factors 
affecting the recurrence were preoperative CEA level ≥5ng/ml, the status of 
lymph node metastasis and MED >5mm (Table 3).  
Multivariate analysis showed that the lymph node metastasis (H.R.: 3.347, 95 % 
CI: 1.834-6.566, p<0.001), preoperative CEA level ≥5ng/ml (H.R. 3.347, 
95 % C.I. 1.620-4.226, p<0.001) and MED >5mm (H.R. 1.661, 95% C.I. 









Figure 2. Disease-free survival rates according to subdivision of 
mesorectal extension depth (MED) 
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(A) There was no significant difference in 5-year disease-free survival rate 
between T3a/T3b (p = 0.35) and T3c/T3d (p = 0.37). (B) Disease-free survival 
rates in the patients with reclassifying with the use of a MED cutoff point of 5 





















  0.454     
 
Male 214 26.7 67.9      
 
Female 77 24.0 70.8      
Age 
 
  0.224     
 
<65 117 28.6 66.0      
 
≥65 114 21.8 72.9      
Histologic grade 
 
  0.110     
 
G1+G2 274 25.0 70.1      
 
G3+G4 17 41.2 43.4      
Venous invasion 
 
  0.149     
 
Positive 84 29.3 54.3      
 
Negative 207 24.6 71.6      
Angiolymphatic 
 





Positive 138 29.4 62.6      
 
Negative 153 22.8 73.6      
Perineural invasion 
 
  0.072     
 
Positive 103 24.5 59.1      
 





  0.583     
 
≤1cm 88 23.3 69.0      
 





  0.134     
 
≤1mm 45 38.6 63.8      
 
>1mm 171 24.7 68.4      
Preoperative CEA 
 
  <0.001  2.617 1.620 - 4.226 <0.001 
 
<5ng/ml 202 18.7 77.0      
 
≥5ng/ml 72 46.5 47.6      
Adjuvant 
chemotherapy  
  0.165 
 
   
 




No 39 18.9 80.7      
Preoperative CRT 
 
  0.165     
 
Yes 91 18.7 75.0      
 
No 200 29.4 66.2      
Lymph node 
metastasis  
  <0.001 
 
3.347 1.834 - 6.566 <0.001 
 
Negative 121 10.3 88.2      
 
Positive 170 36.9 54.8      
Mesorectal 
Extension Depth  
  <0.001 
 
1.661 1.013 - 2.725 0.04 
 
T3ab (≤5mm) 176 17.4 77.6      
 
T3cd (>5mm) 115 38.9 55.2      
Operation procedure 
 








 18 38.9 57.6      
 
Table 3. Risk factors for postoperative recurrence in patients with T3 rectal cancer using univariate and multivariate analysis. 
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3. The prognostic factors for recurrence in patients treated with or without preoperative 
CRT 
Univariate and multivariate regression analyses showed that the lymph node metastasis was the 
most powerful independent risk factor followed by the preoperative CEA level for postoperative 
recurrence in patients with T3 rectal cancer without preoperative CRT (Table 4). In these 
patients, although MED was statistically significant on the univariate analysis, it was not on the 
multivariate analysis. 
 
 Variable Hazard 
Ratio 
95% CI of HR 
P 
value 
pT3 rectal cancer CEA level(≥5ng/ml) 2.479 1.432-4.293 0.001 
Lymph node metastasis 6.067 2.375-15.501 <0.001 
Mesorectal Extension Depth 
 (T3ab/T3cd) 
1.379 0.789-2.412 0.26 
ypT3 rectal cancer CEA level(≥5ng/ml) 3.095 1.112-8.611 0.03 
Mesorectal Extension Depth 
 (T3ab/T3cd) 
2.950 1.082-8.043 0.04 
 
Table 4. Summary of significant factors of all multivariate analyses performed. 
 
Preoperative CRT was delivered to 91 patients. Univariate and multivariate regression analyses 
showed that MED (H.R. 2.950, 95 % C.I. 1.085-8.043, p=0.04) and preoperative CEA level 
(H.R. 3.095, 95 % C.I. 1.112-8.611, p=0.03) were the independent risk factors in these patients. 
In this subgroup, nodal metastasis did not affect recurrence (Table 5). In addition, analysis of 
ypT3 rectal cancer patients according to MED and lymph node status showed lower 5-year 
survival rate of T3cdN- group than that of T3abN+ group (56.3% vs. 79.3%, p=0.27) (Table 6, 




 Variable Univariate analysis  Multivariate analysis 




P value  Hazard 
ratio 
95% CI of H.R. P value 
Sex       0.062     
  Male 71 22.5 68.3       
  Female 20 5.0 94.4       
Age (year)      0.055     
  <65 61 24.6 68.0       
  ≥65 30 6.7 90.5       
Histologic grade      0.501     
  G1+G2  89 19.1 74.4       
  G3+G4  2 0.0 100       
Venous invasion      0.150     
  Positive 28 28.6 60.9       
  Negative 63 14.3 67.7       
Angiolymphatic invasion      0.331     
  Positive 33 24.2 61.9       
  Negative 58 15.5 70.7       
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Perineural invasion      0.243     
  Positive 34 23.5 58.4       
  Negative 57 15.8 69.1       
DRM
b
      0.886     
  ≤1cm 25 20.0 66.4       
  >1cm 66 18.2 78.1       
CRM
c
      0.517     
  ≤1mm 15 26.7 72.7       
  >1mm 48 16.7 74.6       
Preoperative CEA     0.008  3.095 1.112-8.611 0.03 
  <5ng/ml 60 10.0 85.4      
  ≥5ng/ml 29 37.5 59.4      
Adjuvant Chemotherapy     0.135     
  Yes 81 21.0 72.2      
  No 10 0.0 100      
Lymph node metastasis    0.206     
 Negative 49 14.3 79.7      





    0.004  
2.950 1.082-8.043 0.04 
  T3ab (≤5mm) 62 11.3 84.5      
  T3cd (>5mm) 29 34.5 54.9      








 8 37.5 60.0      
Tumor regression grade    0.94     
 
0 (Complete) 0 0 ㅡ      
 
1 (moderate) 53 18.9 75.1      
 
2 (minimal ) 29 20.7 73.9      
 
3 (poor) 1 0 100      
 





ypT3 rectal cancer (n=91) 
No. of patients 5yr DFS (%) p value 
LN- T3ab 37 88.1 0.02 
 
T3cd 12 56.3  
LN+ T3ab 25 79.3 0.08 
 
T3cd 17 52.4  
 
Table 6. Disease-free survival according to MED and lymph node status. 
 
 
Figure 3. Disease-free survival rates according to MED and nodal status are shown. In 
each of ypT3ab and ypT3cd rectal cancer group, there were no significant differences in the 5-
year disease free survival rate according to the nodal status (p = 0.35, p = 0.71). Despite the 
lymph node metastasis, the survival rate of ypT3abN+ patients was higher than that of T3cdN− 




Accurate staging system to categorize patients into relatively homogeneous groups according to 
their prognosis is crucial because these enable clinicians to provide a tailored adjuvant therapy 
or surveillance to patients. The current TNM staging system was refined based on several 
studies identifying prognostic factors for survival and local or distant recurrence. The local 
extent of the primary tumor, lymph node metastases (pT and pN category according to the TNM 
staging system of the UICC/AJCC), angiolymphatic invasion, perineural invasion, and 
preoperative CEA level were found to have prognostic impact based on multiple trials. In 
addition, the prognostic significance of the mesorectal extension depth in rectal cancer was 
advocated in several articles (1-5, 11) . 
Cawthorn et al (4) demonstrated that the patients with mesorectal extension of more than 4mm 
had lower overall survival rate (< 4 mm; 55% vs. ≥ 4 mm; 25%, P < 0.001), but their study had 
some limitations in that they included the patients with rectal cancer without mesorectal 
invasion (stage I) and those who had undergone palliative surgery. For the cut-off value of 3mm 
as independent prognostic factor, the results were inconsistent among authors (5, 9). 
Fore mentioned studies were conducted in a single institute, but Merkel et al. (12) analyzed the 
Erlangen Registry for Colo-Rectal Carcinomas (ERCRC) and the Study Group for Colo-Rectal 
Carcinoma (SGCRC) data. They demonstrated that the 5-year disease-free survival rate was 
significantly higher in tumors with MED 5 mm, compared with tumors with MED >5 mm 
(85.4% vs. 54.1% respectively, p<0.001) in the ERCRC data, but this result could not be 
reproduced in the SGCRC data. Miyoshi et al. (1) determined the optimal cut-off point of 6mm 
using statistical analysis and advocated that the 5-year recurrence-free survival rate in the 
patients with MED < 6mm was higher (69 % vs. 55 %, p<0.05). They measured actual values 
and established the cutoff point in the first data set and validated the prognostic impact of the 
MED of 6mm in the second data set.  
Recently, Shirouzu (7) and Akagi et al (10) analyzed the database from the Study Group of the 
Japanese Society for Cancer of the Colon and Rectum (JSCCR) to determine the optimal cut-off 
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depth of mesorectal invasion for predicting the clinical oncologic outcome in patients with T3 
rectal cancer. They also determined the optimal cut-off point statistically but the value was 
different from that of Miyoshi et al (1). They also advocated that the independent prognostic 
factors for recurrence-free survival in patients with stage T3 rectal cancer were lymph node 
metastasis (H.R.: 2.70, 95 % CI: 2.070-3.525), depth of mesorectal extension, histologic grade 
(H.R.: 1.41, 95 % CI: 1.084-1.833), and lymphatic invasion (H.R.: 1.44, 95 % CI: 1.135-1.838). 
However, in these studies, none of the patients received preoperative radiotherapy or 
neoadjuvant chemotherapy before operative management and more than half of the patients had 
undergone prophylactic lateral pelvic lymph node dissection. These clinical set of patients are 
currently unusual in countries other than Japan. 
In the present study, we confirmed that MED was one of the independent prognostic factors in 
patients with T3 rectal cancer, together with nodal status and CEA level which are already well-
known prognostic factors for colorectal cancer. This study included 91 patients who received 
preoperative CRT. On subgroup analysis of these patients, MED consistently had a significant 
impact on postoperative recurrence rate along with CEA level which had been suggested as a 
useful prognostic factor in patients treated with preoperative CRT by several previous studies. 
(1, 13, 14, 16)  For T3 patients as a whole or T3 patients without preoperative CRT, lymph 
node metastasis was clearly the most important prognostic factor. However, interestingly, nodal 
status was not a significant prognostic factor for ypT3 rectal cancer. It is well known that 
radiotherapy or CRT has an involutional effect on lymphatic tissues and this was reflected as 
decreased number of retrieved lymph nodes in patients treated with preoperative CRT. (17) It 
can be hypothesized that this involutional effect and nodal down staging by preoperative CRT 
might obtund the prognostic impact of lymph node metastasis. So far, most of studies on the 
prognostic impact of the mesorectal extension depth in the T3 rectal cancer included patients 
who did not receive preoperative CRT except for the study by Picon et al. (5) However, they 
argued that the microscopic perirectal fat invasion with cut-off of 3mm could not predict the 
oncologic outcome, but the analysis was not done in subgroup of ypT3 rectal cancer. This study 
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is meaningful in that the current study identified the prognostic significance of MED not only in 
all T3 rectal cancer but also in ypT3 rectal cancer.  
However, there are two limitations in this study. One is that the specimens were examined in 
routine methods rather than by whole mount section by the pathologists. This may compromise 
the accuracy of invasion depth assessment to certain extent as using whole mount section would 
have provided the most accurate depth of invasion. Another limitation is that this study lacks 
identification of TME quality. Plane of surgery has emerged as a significant prognostic factor 
affecting oncologic outcomes in rectal cancer surgery and the importance of pathologic report 
about quality of TME has been highlighted recently. However, most of the patients in our study 
did not have information on the plane of surgery achieved. Leonard et al. (18) dictated that the 
quality of TME shows heterogeneity between surgeons, and the ability of surgeon to stay in the 
mesorectal plane is important in determining the quality of TME. In fact, all the operations 
included in our study were performed by three extremely highly experienced surgeons who have 
performed over thousands of colorectal cancer surgeries. The mesorectal quality of our practice 
was also demonstrated in our randomized prospective trial (COREAN trial (19)) which 
compared laparoscopic and open TME after preoperative chemoradiotherapy. Some of the cases 
in the present study were also enrolled in the COREAN trial. In that trial, the macroscopic TME 
quality was evaluated. For open surgery (n=170), the percentage of complete, nearly complete 
and incomplete was 74.7 %, 13.5 %, and 6.5 %, respectively. For laparoscopic surgery (n=170) 
the percentage was 72.4 %, 19.4%, and 4.7 %, respectively. These results were comparable or 
somewhat superior to other previous studies (20-22).  
In conclusion, the depth of mesorectal extension >5mm is a significant prognostic factor in 
patients with T3 rectal cancer. Especially in patients who received preoperative CRT, the depth 
of mesorectal extension may be more important than the nodal status in predicting the oncologic 
outcome. If these findings can be reproduced or validated in the subsequent studies with larger 
number of cases, T3 substaging according to MED should be incorporated into the rectal cancer 
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서론: 반 수 이상의 직장암 환자가 단일화된 T3 병기로 진단이 되고 있다. 직장암
의 경우, 직장간막의 침범깊이에 따라 예후가 달라지며, 이러한 예후인자가 치료방
법을 결정하는 데 고려되어야 한다는 주장이 제기되고 있다. 이에 이 연구는 T3 직
장암 환자에서 예후인자로서 직장간막 침범깊이의 중요성을 알아보았다. 
 
방법:  서울대병원에서 2003 년 1 월부터 2009 년 12 월까지 근치적 목적으로 수술받
은 T3 병기의 직장암 환자 291 명을 대상으로 하였다. T3 직장암 환자를 직장간막 
침범깊이(mesorectal extension depth, MED)에 따라 분류된 네 아집단의 무병생존율을 
후향적으로 분석하였다. (T3a: <1mm, T3b: 1~5mm, T3c: 5~15mm, T3d: >15mm) 
 
결과: 세분화된 T3 병기 직장암 아집단의 5 년 무병생존률은 각각 T3a, 86.5%; T3b, 
74.2%; T3c, 58.3%; T3d, 29.0%이었다. T3a, b 병기 직장암 환자의 생존율은 77.6%로 
T3c, d 병기 환자들의 생존울인 55.2%보다 통계적으로 유의하게 높았다. (p<0.001) 단
변량 분석 및 다변량 분석에서 종양의 재발에 영향을 주는 예후인자로는 암태아성
항원(CEA) 수치 ≥ 5ng/ml (hazard ratio =2.617, 95% CI 1.620-4.226, 전이된 림프절의 수
(hazard ratio =3.347, 95% CI 1.834-6.566), 직장간막의 침범 깊이 >5mm (hazard ratio 
=1.661, 95% CI 1.013-2.725)이다. 수술 전 항암방사선치료를 받은 200명의 ypT3 직장
암 환자들에서의 예후인자는 수술전 암태아성항원 수치와 직장간막의 침범 깊이이
다. 반면에 91 명의 pT3 직장암 환자의 예후인자는 수술전 암태아성항원 수치와 전




결론:  5mm 이상의 직장간막의 침범깊이는 T3 직장암 환자에 있어 중요한 예후인
자이다. 특히, 이 직장간막의 침범깊이는 수술전 항암방사선치료를 받은 환자들의 
예후를 예측하는데 있어서 림프절 전이보다 더 중요한 인자이다.  
본 내용은 Disease of the Colon & Rectum 학술지 (Dis Colon Rectum 2012; 55: 1220–1228) 
에 출판 완료된 내용임 
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